Pfizer Pipeline. May 9, 2013

Size: px
Start display at page:

Download "Pfizer Pipeline. May 9, 2013"

Transcription

1 Pfizer Pipeline May 9, 2013

2 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 9, Visit Pfizer.com/pipeline, Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2

3 Table of Contents Pfizer Pipeline Snapshot 4 Cardiovascular & Metabolic Diseases 5 Inflammation & Immunology 6 Neuroscience & Pain 7 Oncology 8 Vaccines 9 Other Areas of Focus (including Biosimilars and Rare Diseases) 10 Projects Discontinued Since Last Update 11 3

4 Pfizer Pipeline Snapshot Discovery Projects 2 programs advanced or are new Pfizer Pipeline Snapshot as of May 9, In Reg Total 74 Pipeline represents progress of R&D programs as of May 9, 2013 Included are 56 NMEs, 16 additional indications, plus 2 biosimilars 4 projects discontinued since last update Recent Approval - Bosulif for Treatment of Previously Treated Chronic Myelogenous Leukemia (EU) Discovery Projects 9 programs advanced or are new Pfizer Pipeline Snapshot as of February 28, In Reg Total 78 Pipeline represents progress of R&D programs as of February 28, 2013 Included are 61 NMEs, 15 additional indications, plus 2 biosimilars 4 projects discontinued since last update Recent Approval - Eliquis for Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U.S./EU) 4

5 Pfizer Pipeline May 9, 2013 Therapeutic Area Cardiovascular and Metabolic Diseases Compound Name Mechanism of Action ( 3 through regulatory approval) Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Prevention (U.S.) 3 Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Treatment 3 ertugliflozin (PF ) Diabetes Mellitus-Type 2 2 RN316 (PF ) Hypercholesterolemia (Biologic) 2 PF Diabetes Mellitus-Type 2 2 PF Diabetic Nephropathy 2 PF Diabetic Nephropathy 2 PF Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 1 RN317 (PF ) Hypercholesterolemia (Biologic) 1 PF Acute Coronary Syndrome 1 5

6 Pfizer Pipeline May 9, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tofacitinib JAK Inhibitor Rheumatoid Arthritis (EU) Registration Xeljanz (tofacitinib) JAK Inhibitor Psoriasis (Oral) 3 Xeljanz (tofacitinib) JAK Inhibitor Ulcerative Colitis 3 PF Rheumatoid Arthritis 2 PF Ulcerative Colitis (Biologic) 2 anrukinzumab (IMA-638) Ulcerative Colitis (Biologic) 2 Inflammation and Immunology PF Crohn s Disease, Ulcerative Colitis (Biologic) 2 PF Crohn s Disease, Lupus (Biologic) 2 PH Chronic Obstructive Pulmonary Disease 2 PD Sarcoidosis, *Lupus (Biologic) 2 PF (EXC 001) Dermal Scarring 2 Xeljanz (tofacitinib) Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn s Disease 2 Dekavil Rheumatoid Arthritis (Biologic) 1 PF Chronic Obstructive Pulmonary Disease 1 PF Diabetes Mellitus-Type 1 (Biologic) 1 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com * Note: Additional indications in 1 6

7 Pfizer Pipeline May 9, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Celebrex COX-2 Chronic Pain (U.S.) Registration Neuroscience & Pain Remoxy ALO-02 Oxycodonenaltrexone core Mu-type opioid receptor (MOR-1) Agonist Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain (U.S.) Registration Moderate to Severe Pain 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain 3 Lyrica Alpha-2 Delta Ligand CR (once a day dosing) 3 tanezumab Nerve Growth Factor Inhibitor OA Signs and Symptoms (Biologic) (on clinical hold) 3 PF (SAM-760) Alzheimer s Disease 2 PF Stroke Recovery 2 tanezumab Cancer Pain (Biologic) 2 PF Chronic Pain 1 PF (AAB-003) Alzheimer s Disease (Biologic) 1 PF Schizophrenia 1 PF Chronic Pain 1 PF Acute and Chronic Pain 1 7

8 Pfizer Pipeline May 9, 2013 (cont d) Therapeutic Area Oncology Compound Name dacomitinib (PF ) dacomitinib (PF ) Mechanism of Action ( 3 through regulatory approval) pan-her Inhibitor Previously Treated Advanced Non-Small Cell Lung Cancer 3 pan-her Inhibitor 1 st Line Non-Small Cell Lung Cancer 3 Xalkori (crizotinib) c-met-alk Inhibitor ALK-Positive 1st and 2nd Line (supports potential full approval in the U.S.) Non- Small Cell Lung Cancer, *Cancer 3 Inlyta (axitinib) VEGF Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant (Asia only) 3 Sutent Multiple Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant 3 palbociclib (PD ) CDK 4,6 Kinase Inhibitor 1 st Line Advanced Breast Cancer, *Cancer 3 inotuzumab ozogamicin Aggressive Non-Hodgkin Lymphoma (Biologic) i 3 inotuzumab ozogamicin Acute Lymphoblastic Leukemia (Biologic) 3 Inlyta (axitinib) Liver Cancer 2 dacomitinib (PF ) Cancer 2 PF Endometrial Cancer, *Cancer 2 PF Cancer 1 PF Cancer (Biologic) 1 PD Cancer (in combination with PF ) 1 PF Cancer (Biologic) 1 PF Acute Myelocytic Leukemia 1 * Note: Additional indications in 1 8

9 Pfizer Pipeline May 9, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Vaccines MnB rlp2086 (PF ) Adolescent and Young Adult Meningitis B 3 ACC-001 (PF ) Alzheimer s Disease 2 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF ) Staph Aureus 2 PF Smoking Cessation 1 PF Clostridium Difficile Colitis 1 PF Asthma 1 9

10 Pfizer Pipeline May 9, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Other Areas of Focus (Rare Diseases) tafamidis meglumine PF (GMI-1070) Transthyretin (TTR) Dissociation Inhibitor Transthyretin familial amyloid polyneuropathy (U.S.) Vaso-occlusive crisis associated with Sickle Cell Disease Registration 2 PF Hemophilia (Biologic) 1 PF Muscular Dystrophies (Biologic) 1 PF Spinal Muscular Atrophy 1 Other Areas of PF Rheumatoid Arthritis (Biosimilar) 1 Focus (Biosimilars) PF Metastatic Breast Cancer (Biosimilar) 1 Other Areas of Focus bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms (U.S.) / (EU) Registration Viviant Selective Estrogen Receptor Modulator Osteoporosis Treatment and Prevention (U.S.) Registration Zithromax/chloroquine 5-OS Ribosome Inhibitor Malaria 3 bosutinib Autosomal Dominant Polycystic Kidney Disease 2 PNU Tuberculosis 2 Biosimilar 10

11 Projects Discontinued from Development since February 28, 2013 Compound Name Mechanism of Action ( 3 through regulatory approval) RN6G (PF ) Age-Related Macular Degeneration (Biologic) 2 PF Cancer (Biologic) 1 CVX 096 (PF ) Diabetes Mellitus-Type 2 (Biologic) 1 CVX 060 (PF ) Renal Cell Carcinoma, *Cancer (Biologic) 1 * Note: Additional indications in 1 11

Pfizer Pipeline. As of February 27, 2015

Pfizer Pipeline. As of February 27, 2015 Pfizer Pipeline As of February 27, 2015 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses (MOA) information for

More information

Pfizer Pipeline. As of February 2, 2016

Pfizer Pipeline. As of February 2, 2016 Pfizer Pipeline As of February 2, 2016 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses (MOA) information for

More information

Co-pay assistance organizations offering assistance

Co-pay assistance organizations offering assistance Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin

More information

To Our Shareholders. 2013: Keeping Our Commitments, Continuing Our Momentum. Continued Transformation of Our Innovative Core. Annual Review 2013

To Our Shareholders. 2013: Keeping Our Commitments, Continuing Our Momentum. Continued Transformation of Our Innovative Core. Annual Review 2013 To Our Shareholders In 2013, Pfizer achieved solid results for patients, consumers, and shareholders by maintaining our focus on developing new therapies, driving growth, and delivering value. Ian C. Read

More information

Fourth Quarter 2015 Earnings Teleconference. February 2, 2016

Fourth Quarter 2015 Earnings Teleconference. February 2, 2016 Fourth Quarter 2015 Earnings Teleconference February 2, 2016 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information Our discussions

More information

Leading In Biopharmaceutical Innovation

Leading In Biopharmaceutical Innovation STRONGER BUSINESS OUR BUSINESSES Leading In Biopharmaceutical Innovation Our businesses include five prescription-only biopharmaceutical businesses and Pfizer Consumer Healthcare. Primary Care, Specialty

More information

Phoenix Remembrance Life

Phoenix Remembrance Life Phoenix Remembrance Life W e You Asked New Printer- Friendly Design! D e l i v e r e d Field Underwriting Guide For agent use only. Not for distribution to the public as sales literature. Phoenix Remembrance

More information

Limited Pay Policy (L-222B) - Underwriting Guidelines

Limited Pay Policy (L-222B) - Underwriting Guidelines Limited Pay Policy (L-222B) - Underwriting Guidelines 1 Addiction/Abuser Drug - Past or Present Presently Recovered - AA for last 2 years 2 Aids 3 Alcoholic Presently Recovered - AA for last 2 years 4

More information

Medicare Supplement Plans Underwriting and Administration Guide

Medicare Supplement Plans Underwriting and Administration Guide Medicare Supplement Plans Underwriting and Administration Guide 024227 (09-2011) Table of Contents Introduction....1 Underwriting Concepts...1 Coverage....1 Eligibility Requirements...1 Eligibility Considerations...1

More information

Pfizer Primary Care Business

Pfizer Primary Care Business 1 Pfizer Primary Care Business November 10, 2010 Pfizer Primary Care Olivier Brandicourt President and General Manager Primary Care Business Unit November 10, 2010 Forward-Looking Statements and Non-GAAP

More information

Covers 60 major critical illnesses. Covers 11 minor critical illnesses. ManuMulti Care

Covers 60 major critical illnesses. Covers 11 minor critical illnesses. ManuMulti Care It s a difficult subject to think about, but part of planning for the future is being prepared for the unexpected. Critical illness can happen to anyone, at any time. And it s an unfortunate fact, but

More information

Phoenix Simplicity Index Life SM

Phoenix Simplicity Index Life SM Phoenix Simplicity Index Life SM Field Underwriting Guide Phoenix Simplicity Index Life is indexed universal life insurance underwritten on a simplified issue basis. There are no medical examinations,

More information

Progressive Care Insurance for life A NEW TYPE OF INSURANCE

Progressive Care Insurance for life A NEW TYPE OF INSURANCE Progressive Care Insurance for life A NEW TYPE OF INSURANCE New Progressive Care from Sovereign Progressive Care is a type of insurance that is new to New Zealand. It s not a traditional all-or-nothing

More information

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer

More information

PFIZER REPORTS THIRD-QUARTER 2015 RESULTS

PFIZER REPORTS THIRD-QUARTER 2015 RESULTS PFIZER REPORTS THIRD-QUARTER 2015 RESULTS Third-Quarter 2015 Reported Revenues (1) of $12.1 Billion Increased 6% Operationally, Which Includes $0.3 Billion Reflecting One Month of Legacy Hospira U.S. Operations

More information

A Source of Hard- to- Find Pa3ents and Caregivers For Researchers. Peter Ziedins Peter.ziedins@mpiresearch.ca 514-426- 9295 www.rarepa;entvoice.

A Source of Hard- to- Find Pa3ents and Caregivers For Researchers. Peter Ziedins Peter.ziedins@mpiresearch.ca 514-426- 9295 www.rarepa;entvoice. A Source of Hard- to- Find Pa3ents and Caregivers For Researchers Peter Ziedins Peter.ziedins@mpiresearch.ca 514-426- 9295 www.rarepa;entvoice.com About RPV Rare Pa3ent Voice, LLC was formed to provide

More information

Development Pipeline & Key Development Projects

Development Pipeline & Key Development Projects Development Pipeline & Key Development Projects May 25, 2009 FY2008 Business Results Briefing Hotel Metropolitan Edmont Ken-ichi Yanagisawa Board Director Managing Executive Officer Development Division

More information

Medical Matters Action Checklists

Medical Matters Action Checklists Medical Matters Action Checklists The following Action Checklists are included in Chapter 5: Medical History Personal Medication Record Health Care Power of Attorney Medical Orders (Do Not Resuscitate/POLST)

More information

NEWS FROM THERAPEUTIC AREAS

NEWS FROM THERAPEUTIC AREAS HIGHLIGHTS IN MEDICINE IN 2014 NEWS FROM THERAPEUTIC AREAS Research, development and medicine at Boehringer Ingelheim can look back on yet another very successful year. Research, development and medicine

More information

Critical PROVIDER FIELD UNDERWRITING GUIDE & RATE BOOK

Critical PROVIDER FIELD UNDERWRITING GUIDE & RATE BOOK G T L Critical PROVIDER FIELD UNDERWRITING GUIDE & RATE BOOK 10 OR 20 YEAR RENEWABLE TERM LIFE INSURANCE WITH A CRITICAL ILLNESS ACCELERATED BENEFIT RIDER WHICH PROVIDES CASH BENEFITS FOR 18 CRITICAL CONDITIONS

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

Patient Information. Name: Social Security Number: Birth date: Email: Address: Phone #: House: Cell: Work: Primary Care Physician: Address:

Patient Information. Name: Social Security Number: Birth date: Email: Address: Phone #: House: Cell: Work: Primary Care Physician: Address: Patient Information Name: Social Security Number: Birth date: Age: Email: Address: Phone #: House: Cell: Work: Primary Care Physician: Phone #: Date Last Visit: Address: Emergency Contact: Emergency Phone

More information

Medical Surgical Nursing (Elsevier)

Medical Surgical Nursing (Elsevier) 1 of 6 I. The Musculoskeletal System Medical Surgical Nursing (Elsevier) 1. Med/Surg: Musculoskeletal System: The Comprehensive Health History 2. Med/Surg: Musculoskeletal System: A Nursing Approach to

More information

Methotrexate Dose For Juvenile Rheumatoid Arthritis

Methotrexate Dose For Juvenile Rheumatoid Arthritis Methotrexate Dose For Juvenile Rheumatoid Arthritis should i take methotrexate for my ra methotrexate 50 mg/ml methotrexate sodium 2.5mg tablets what is the usual dosage of methotrexate for ra methotrexate

More information

Bayer Accelerates Clinical Development of Promising New Drug Candidates

Bayer Accelerates Clinical Development of Promising New Drug Candidates Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Accelerates Clinical Development of Promising New Drug Candidates Five

More information

How To Get A Chronic Illness Benefit From The Discovery Health Medical Scheme

How To Get A Chronic Illness Benefit From The Discovery Health Medical Scheme Cover for medicine and treatment of chronic conditions 2014 Cover for medicine and treatment of chronic conditions 22 November 2013 Page 1 of 16 Cover for medicine and treatment of chronic conditions Overview

More information

RECORD OF COMMERCIAL SUCCESS

RECORD OF COMMERCIAL SUCCESS MULTIPLE SCLEROSIS HEMOPHILIA CD-20 THERAPIES RECORD OF COMMERCIAL SUCCESS 5 5 Note: Rituxan and Gazyva are in collaboration with Roche Revenues ($B) Non-GAAP Diluted EPS ($) +18% CAGR +24% CAGR 12.09

More information

Asteron Life Personal Insurance

Asteron Life Personal Insurance Asteron Life Personal Insurance What lump sum covers are available with Asteron Life Personal Insurance? Life Cover Life Cover insurance pays a lump sum of money if you pass away or become terminally ill.

More information

Core therapeutic areas

Core therapeutic areas Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014

More information

Building Bridges to Long-Term Growth

Building Bridges to Long-Term Growth N o 7 Building Bridges to Long-Term Growth Tanabe is working to realize its corporate philosophy of contributing to people over the world desiring to live healthy and securely through pharmaceuticals and

More information

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This

More information

FY2015 Press Conference

FY2015 Press Conference FY2015 Press Conference -Turn innovative science into value for patients- December 8 th, 2015 Yoshihiko Hatanaka President and CEO Astellas Pharma Inc. 0 Cautionary Statement Regarding Forward-Looking

More information

Asteron Life Business Insurance

Asteron Life Business Insurance Asteron Life Business Insurance What lump sum covers are available with Asteron Life Business Insurance? Life Cover Life Cover pays a lump sum of money if you pass away or become terminally ill. Total

More information

Patient & Medical Professional US Online Panel

Patient & Medical Professional US Online Panel Patient & Medical Professional US Online Panel Patient & Medical Professional US Online Panel Over 500K validated US online double opt-in panelists motivated to share their opinions in research! Since

More information

One (1) single qualifying condition of either HIV/AIDS or a Serious Mental Illness (SMI)

One (1) single qualifying condition of either HIV/AIDS or a Serious Mental Illness (SMI) Eligibility Criteria for Health Home Services: Chronic Conditions New York State s Health Home eligibility criteria is as follows: Medicaid eligible/active Medicaid; and Two (2) or more chronic conditions;

More information

SUPER CARE CRITICAL ILLNESS PROTECTOR

SUPER CARE CRITICAL ILLNESS PROTECTOR SUPER CARE CRITICAL ILLNESS PROTECTOR At ACE Life, we are committed to helping our valued customers achieve financial security and have a peace of mind through our comprehensive range of life insurance

More information

Phoenix Safe Harbor Term Life Express SM

Phoenix Safe Harbor Term Life Express SM Phoenix Safe Harbor Term Life Express SM Quick Reference Guide For agent use only. Not for distribution to the public as sales literature. Table of Contents Product Overview... 3 Accelerated Benefit Rider

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Social Security No. - - Male Female E-mail Issue Age. City State ZIP - Personal Phone No. ( ) - Birth State/Country Height ft. in. Weight lbs.

Social Security No. - - Male Female E-mail Issue Age. City State ZIP - Personal Phone No. ( ) - Birth State/Country Height ft. in. Weight lbs. PLEASE PRINT WITH BLACK INK ASSURITY LIFE INSURANCE COMPANY 1526 K Street, PO Box 82533, Lincoln NE 68501-0926 Primary Proposed Insured - Employee APPLICATION FOR INSURANCE New application Takeover Addition,

More information

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes

More information

Long Term Care Insurance - Application for Coverage

Long Term Care Insurance - Application for Coverage Long Term Care Insurance - Application for Coverage How to apply for coverage. 1. Each person (member, spouse, parent, and/or adult child) applying for Long Term Care coverage must complete and submit

More information

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,

More information

Patient Medical History

Patient Medical History Cardiovascular Abnormal Electrocardiogram Aortic Stenosis Atrial fibrillation Cardiac arrest Chest pain Congestive heart failure Heart valve replacement Hypertension Murmur Heart attack Palpitations Peripheral

More information

The Patient Access Network (PAN) Foundation Eligibility Diseases Targeted Contact Information

The Patient Access Network (PAN) Foundation Eligibility Diseases Targeted Contact Information The Patient Access Network (PAN) Foundation is an independent non-profit organization that provides assistance to underinsured patients for their out-of-pocket expenses through more than 40 disease-specific

More information

How To Choose A Biologic Drug

How To Choose A Biologic Drug North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.

More information

List of Qualifying Conditions

List of Qualifying Conditions List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)

More information

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW Clinical Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW NQF 0105 PQRS 9 NQF 0002 PQRS 66 Antidepressant Medication Management Appropriate Testing for Children with Pharyngitis (2-18 years)

More information

Chronic Illness Benefit application form 2011

Chronic Illness Benefit application form 2011 Contact us Tel: 0860 99 88 77, PO Box 784262, Sandton, 2146, www.discovery.co.za Chronic Illness Benefit application form 2011 This application form is to apply for the Chronic Illness Benefit and is only

More information

Medicare Supplement Application Aetna Life Insurance Company Aetna Administrator, P.O. Box 10374, Des Moines, IA 50306

Medicare Supplement Application Aetna Life Insurance Company Aetna Administrator, P.O. Box 10374, Des Moines, IA 50306 Medicare Supplement Application Aetna Administrator, P.O. Box 10374, Des Moines, IA 50306 INSTRUCTIONS: To be considered complete, all sections on this form must be filled out, unless marked optional.

More information

National Health and Wellness Survey. The Global Health and Wellness Report

National Health and Wellness Survey. The Global Health and Wellness Report National Health and Wellness Survey The Global Health and Wellness Report Introduction National Health and Wellness Survey 2 Table of Contents About Kantar Health... 3 The National Health and Wellness

More information

Critical Illness with Term Assurance

Critical Illness with Term Assurance AIG Life Critical Illness with Term Assurance Our comprehensive Critical Illness with Term Assurance delivers more value and quality to the customer and their family than ever before. It is designed to

More information

Life Living Assurance Customer guide LIVING ASSURANCE. TotalCareMax Customer guide. Life. Take charge. sovereign.co.nz

Life Living Assurance Customer guide LIVING ASSURANCE. TotalCareMax Customer guide. Life. Take charge. sovereign.co.nz Life Living Assurance Customer guide LIVING ASSURANCE TotalCareMax Customer guide Life. Take charge. sovereign.co.nz WHAT IS LIVING ASSURANCE? Living Assurance provides you and your family with peace of

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

Medical Specialties Guide

Medical Specialties Guide Medical Specialties Guide Allergy And Immunology Specialists in this field treat disorders related to how the body reacts to foreign substances. They treat such things as seasonal allergies, eczema, asthma,

More information

Scientifically Minded. Medically Driven.

Scientifically Minded. Medically Driven. Scientifically Minded. Medically Driven. MEDICALLY DRIVEN. 01 SCIENTIFICALLY MINDED. At Worldwide Clinical Trials we strategically balance science, medicine, operations and commercial intelligence to achieve

More information

GUIDE. Prepare for Your Phone Interview and Medical Exam.

GUIDE. Prepare for Your Phone Interview and Medical Exam. GUIDE Prepare for Your Phone Interview and Medical Exam. WHAT YOU NEED TO HAVE, KNOW, AND DO. All information gathered during the interview and exam will be shared only with those who need it in order

More information

Bone Basics National Osteoporosis Foundation 2013

Bone Basics National Osteoporosis Foundation 2013 Certain people are more likely to develop osteoporosis than others. While you have no control over some risk factors for osteoporosis, there are others you can change. By making healthier choices you can

More information

SOUTH PALM CARDIOVASCULAR ASSOCIATES, INC. CHARLES L. HARRING, M.D. NEW PATIENT INFORMATION FORM. Patient Name: Home Address:

SOUTH PALM CARDIOVASCULAR ASSOCIATES, INC. CHARLES L. HARRING, M.D. NEW PATIENT INFORMATION FORM. Patient Name: Home Address: NEW PATIENT INFORMATION FORM Today s Date: Referred by: Patient Name: (First) (Last) Date of Birth: Gender: M / F SSN: Home Address: Home Phone (Area Code & No.): ( ) - Cell Phone: ( ) - Secondary Address

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

Maria Iachina, Anders Green, Erik Jakobsen, Anders Mellemgaard, Mark Krasnik, Margreet Lüchtenborg, Henrik Møller

Maria Iachina, Anders Green, Erik Jakobsen, Anders Mellemgaard, Mark Krasnik, Margreet Lüchtenborg, Henrik Møller The effect of different comorbidity groups on the survival of patients with non-small cell lung cancer Maria Iachina, Anders Green, Erik Jakobsen, Anders Mellemgaard, Mark Krasnik, Margreet Lüchtenborg,

More information

(Intro to Arthritis with a. Arthritis) Manager of Education & Services for the Vancouver Island Region of The Arthritis Society

(Intro to Arthritis with a. Arthritis) Manager of Education & Services for the Vancouver Island Region of The Arthritis Society Arthritis 101 (Intro to Arthritis with a Focus on Rheumatoid Arthritis) by Cari Taylor by Cari Taylor Manager of Education & Services for the Vancouver Island Region of The Arthritis Society What You Will

More information

Restore and Maintain treatment protocol

Restore and Maintain treatment protocol Restore and Maintain treatment protocol Combating inflammation through the modulation of eicosanoids Inflammation Inflammation is the normal response of a tissue to injury and can be triggered by a number

More information

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease 80 Liver Disease and Obesity Liver disease biomarkers: Percent of adult population (United States)

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife

More information

It s not something you want to think about, but it s something you want to prepare for.

It s not something you want to think about, but it s something you want to prepare for. It s not something you want to think about, but it s something you want to prepare for. StemCyte cord blood banking offers your family a new lifesaving treatment alternative Why Bank Take the once-in-alifetime

More information

Chronic Illness Benefit application form 2016

Chronic Illness Benefit application form 2016 Chronic Illness Benefit application form 2016 This application form is to apply for the Chronic Illness Benefit and is only valid for 2016 Contact us Tel (Members): 0860 99 88 77, Tel (Health Professionals):

More information

Management in the pre-hospital setting

Management in the pre-hospital setting Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,

More information

2. APPLICANT S NAME, HOME ADDRESS AND APPLICANT S MAILING ADDRESS (If different from your home address.)

2. APPLICANT S NAME, HOME ADDRESS AND APPLICANT S MAILING ADDRESS (If different from your home address.) AGENT & OFFICE USE ONLY Date Received: Group Number: Effective Date: Agent Number: Agency Number: APPLICATION FOR MEDICARE SUPPLEMENT PROGRAM MEDIGAP BLUE 1. ELIGIBILITY If you are not eligible for Medicare

More information

Patient Interview Form

Patient Interview Form Patient Interview Form www.austingastro.com Patient Information First Name: Date Of Birth: Last Name: Age: Email Please check one as your preferred email for communications Personal: Work: Race Select

More information

Clinical VantageSM. A Winning Advantage. Commanding. Comprehensive. Strategic. That s Clinical Vantage, a suite of clinical programs from

Clinical VantageSM. A Winning Advantage. Commanding. Comprehensive. Strategic. That s Clinical Vantage, a suite of clinical programs from SM Clinical Vantage Clinical VantageSM A Winning Advantage Commanding. Comprehensive. Strategic. That s Clinical Vantage, a suite of clinical programs from Prescription Solutions designed to fit your pharmacy

More information

Jeff Kindler. Chief Executive Officer

Jeff Kindler. Chief Executive Officer Jeff Kindler Chief Executive Officer 1 Maximizing Current Performance Raising 2006 EPS guidance Forecasting high single digit average annual adjusted diluted EPS growth in 2007-2008 over higher 2006 base

More information

RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 2014

RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 2014 1. 2. RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 214 3.1 Coronary Heart Disease (CHD) 3.2 Heart Failure 1 3.3 Heart Failure 3 (heart failure due to Left Ventricular Systolic Dysfunction) 3.4 Stroke

More information

Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions

Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions IMPORTANCE OF HORMONE BALANCE Importance of Hormone Balance Help you live a long, healthy life Help you

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

(212) 733-2324 mackay.jimeson@pfizer.com

(212) 733-2324 mackay.jimeson@pfizer.com For immediate release: July 9, 2012 Media Contacts: MacKay Jimeson (212) 733-2324 mackay.jimeson@pfizer.com Pfizer Recognizes 10 th Anniversary Of The Women s Health Initiative: A Modern Day Perspective

More information

Electronic Health Record Strategies for Pay for Performance. James O Connor MD Director of Clinical Informatics

Electronic Health Record Strategies for Pay for Performance. James O Connor MD Director of Clinical Informatics Electronic Health Record Strategies for Pay for Performance This Title is Copy where the title would go. James O Connor MD Director of Clinical Informatics Early Days of EMR... Access to Records E&M Coding

More information

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market

More information

Annual Press Conference 2012. Business Year 2011

Annual Press Conference 2012. Business Year 2011 Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation

More information

HOW TO SUCCEED IN VALUE-BASED, PATIENT- CENTERED HEALTHCARE

HOW TO SUCCEED IN VALUE-BASED, PATIENT- CENTERED HEALTHCARE Health and Life Sciences POINT OF VIEW SEPTEMBER 2014 HOW TO SUCCEED IN VALUE-BASED, PATIENT- CENTERED HEALTHCARE A BRIEFING FOR MEDICAL DEVICE COMPANIES AUTHORS J. David Campbell, Partner Terry Stone,

More information

Autoimmune Diseases More common than you think Randall Stevens, MD

Autoimmune Diseases More common than you think Randall Stevens, MD Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system

More information

SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE

SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE DEMOGRAPHIC INFORMATION Patient Name: Date: Address: City: State: Zip Code Best Phone Number: Marital Status Phone (H): (W) (Cell):

More information

APPLICATION FOR MEDICARE SUPPLEMENT COVERAGE

APPLICATION FOR MEDICARE SUPPLEMENT COVERAGE CENTRAL STATES INDEMNITY CO. OF OMAHA Home Office: Omaha, NE Administration: P.O. Box 10816 Clearwater, Florida 33757-8816 APPLICATION FOR MEDICARE SUPPLEMENT COVERAGE SECTION A. PROPOSED INSURED INFORMATION

More information

Please print in black ink. TO BE COMPLETED BY APPLICANT Applicant's Name DOB Sex Last First MI Month/Day/Year

Please print in black ink. TO BE COMPLETED BY APPLICANT Applicant's Name DOB Sex Last First MI Month/Day/Year Application for Short-Term Disability Insurance (A-57400 Series) Application to American Family Life Assurance Company of Columbus (AFLAC) Worldwide Headquarters: Columbus, Georgia 31999 New Conversion

More information

Chronic Illness Benefit application form 2016

Chronic Illness Benefit application form 2016 Chronic Illness Benefit application form 2016 This application form is to apply for the Chronic Illness Benefit and is only valid for 2016 Contact details Tel: 0860 116 116, PO Box 652509, Benmore 2010,

More information

REGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm)

REGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm) REGULATIONS FOR THE DEGREE OF MASTER OF CLINICAL PHARMACY (MClinPharm) (See also General Regulations) MCP1 Definition The degree of Master of Clinical Pharmacy (MClinPharm) is a postgraduate degree awarded

More information

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets

More information

SECTION I: ACTIVE DIAGNOSES

SECTION I: ACTIVE DIAGNOSES SECTION I: ACTIVE DIAGNOSES Intent: The items in this section are intended to code diseases that have a direct relationship to the resident s current functional status, cognitive status, mood or behavior

More information

Group 2: Critical Illness Benefits

Group 2: Critical Illness Benefits Group 2: Zurich s cover is designed to free yourself and your loved ones from the potentially devastating financial impact that follows diagnosis with a critical illness. 1. Level Term Life or Earlier

More information

Chronic Illness Benefit application form 2014

Chronic Illness Benefit application form 2014 Chronic Illness Benefit application form 2014 This application form is to apply for the Chronic Illness Benefit and is only valid for 2014 Contact us Tel: 0860 99 88 77, PO Box 784262, Sandton, 2146, www.discovery.co.za

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

ODM Care Management Excel File and Submission Specifications

ODM Care Management Excel File and Submission Specifications ODM Care Management Excel File and Submission Specifications Issued: September 2013 1 Table of Contents 1. Introduction...3 2. HIPAA Security Measures...3 3. Care Management Certification Form.....3 4.

More information

MEASURING CARE QUALITY

MEASURING CARE QUALITY MEASURING CARE QUALITY Region November 2015 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance

More information

Boston, May 6-7, 2015

Boston, May 6-7, 2015 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller Head of Bayer HealthCare Global Development Boston, May 6-7, 2015 Page 1 Deutsche Bank 40th Annual Health Care Conference Joerg Moeller May

More information

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG Demystifying Stem Cells Brent Bost M.D., CPA, MBA, FACOG Disclaimers Author currently serves on Board of Directors of CordTrack Most applications discussed today are not currently FDA approved and are,

More information

PHC4 35 Diseases, Procedures, and Medical Conditions for which Laboratory Data is Required Effective 10/1/2015

PHC4 35 Diseases, Procedures, and Medical Conditions for which Laboratory Data is Required Effective 10/1/2015 PHC4 35 Diseases, Procedures, and Medical Conditions for which Laboratory Data is Required Effective 10/1/2015 Laboratory data is to be submitted for discharges in the following conditions: 1. Heart Attack

More information

Phoenix Remembrance Life

Phoenix Remembrance Life Phoenix Remembrance Life Put to work for you! Quick Reference Guide See page 7 for details. Click here to try it today Product Overview... 1 Customization Options... 3 Quotes... 5 Completing the Application...

More information

Summary of the risk management plan (RMP) for Accofil (filgrastim)

Summary of the risk management plan (RMP) for Accofil (filgrastim) EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure

More information

First Name. Profession. Weight lbs. Weight 1 year ago lbs. Min. Adult Weight lbs. at age Maximum Weight lbs. at age

First Name. Profession. Weight lbs. Weight 1 year ago lbs. Min. Adult Weight lbs. at age Maximum Weight lbs. at age Date Time Dietary consultation involves a health profile whose purpose is not to establish a diagnosis, but rather to determine a client's health status in order to guide his or her weight loss plan. A

More information